Pharmaceutical composition of a papillomavirus inhibitor
The invention relates to a pharmaceutical composition including a compound of general formula (I) combined with a solvent and a viscosity-enhancing agent, as well as to the use thereof as a drug, in particular for treating and preventing infection with the papillomavirus, and to the method for preparing same.
1. A pharmaceutical composition including a compound of general formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
G 1 represents a bond or a linear and saturated hydrocarbon chain comprised of 1 to 4 carbon atoms,
A represents an aryl group optionally substituted:
in the meta or para position by an alkoxy group or by an aryl or arylalkyl group, optionally substituted by one or two substituents, identical or different, selected from the group consisting of acyl and alkoxy,
B represents an aryl group substituted in the ortho position by an N-cycloalkyl, and optionally substituted in the ortho′ position by an alkyl group,
n is an integer between 1 and 2,
R1 represents an alkoxy group in the ortho position in relation to R3,
R2 represents a hydrogen or halogen atom, or an alkyl group in the meta position in relation to R3, and
R3 represents an acid group;
in combination with a solvent and a viscosity-enhancing agent,
wherein the composition is in gel form, and wherein the gel has a viscosity of 5,000 to 50,000 mPa·s.
2. The pharmaceutical composition according to claim 1 , comprising 0.01 to 10% by weight of the compound of formula (I) in relation to the total weight of the pharmaceutical composition.
3. The pharmaceutical composition according to claim 2 , comprising 2 to 8% by weight of the compound of formula (I) in relation to the total weight of the pharmaceutical composition.
4. The pharmaceutical composition according to claim 1 , wherein the viscosity-enhancing agent is hydroxypropylcellulose, hydroxypropylmethylcellulose, a carbomer or a mixture thereof.
5. The pharmaceutical composition according to claim 4 , wherein the viscosity-enhancing agent is hydroxypropylcellulose.
6. The pharmaceutical composition according to claim 1 , comprising 0.01 to 50% by weight of viscosity-enhancing agent in relation to the total weight of the pharmaceutical composition.
7. The pharmaceutical composition according to claim 6 , comprising 0.5 to 5% by weight of viscosity-enhancing agent in relation to the total weight of the pharmaceutical composition.
8. The pharmaceutical composition according to claim 1 , wherein the solvent is propylene glycol, glycerol, polyethylene glycol or a mixture thereof.
9. The pharmaceutical composition according to claim 8 , wherein the solvent is propylene glycol.
10. The pharmaceutical composition according to claim 1 , comprising 40 to 99.9% by weight of solvent in relation to the total weight of the pharmaceutical composition.
11. The pharmaceutical composition according to claim 10 , comprising 85 to 99% by weight of solvent in relation to the total weight of the pharmaceutical composition.
12. The pharmaceutical composition according to claim 11 , comprising 90 to 95% by weight of solvent in relation to the total weight of the pharmaceutical composition.
13. The pharmaceutical composition according to claim 1 , including, in relation to the total weight of the pharmaceutical composition:
0.01 to 10% by weight of the compound of formula (I),
0.01 to 50 by weight of viscosity-enhancing agent, and
40 to 99.9% by weight of solvent.
14. The pharmaceutical composition according to claim 13 , including, in relation to the total weight of the pharmaceutical composition:
0.01 to 10% by weight of the compound of formula (I),
0.05 to 10% by weight of a viscosity-enhancing agent selected from hydroxypropylcellulose, hydroxypropylmethylcellulose, a carbomer and mixtures thereof, and
80 to 99.5% by weight of a solvent selected from propylene glycol, glycerol, polyethylene glycol and mixtures thereof.
15. The pharmaceutical composition according to claim 14 , having the following composition in relation to the total weight of the pharmaceutical composition:
0.01 to 10% by weight of the compound of formula (I),
0.05 to 10% by weight of hydroxypropylcellulose, and
80 to 99.5% by weight of propylene glycol.
16. The pharmaceutical composition according to claim 15 , having the following composition in relation to the total weight of the pharmaceutical composition:
2 to 8% by weight of the compound of formula (I),
0.5 to 5% by weight of hydroxypropylcellulose, and
90 to 95% by weight of propylene glycol.
17. The pharmaceutical composition according to claim 1 , wherein the gel has a viscosity of 15,000 to 25,000 mPa·s.
18. The pharmaceutical composition according to claim 1 , wherein the compound of formula (I) has the following features:
A represents a phenyl group substituted in the para position by a benzyl group,
B represents a phenyl group substituted in the ortho position by a piperidin-1-yl group and in the ortho′ position by a methyl group, and
G1 represents a bond.
19. The pharmaceutical composition according to claim 1 , wherein the compound of formula (I) is 4-[N′-(4-benzyl-phenyl)-N′-(2-methyl-6-piperidin-1-yl-phenyl)-hydrazinocarbonylmethyl]-5-bromo-2-methoxy-benzoic acid or a pharmaceutically acceptable salt thereof.
20. The pharmaceutical composition according to claim 19 , wherein the compound of formula (I) is the potassium salt of 4-[N′-(4-benzyl-phenyl)-N′-(2-methyl-6-piperidin-1-yl-phenyl)-hydrazinocarbonylmethyl]-5-bromo-2-methoxy-benzoic acid.
21. A method for preparing a pharmaceutical composition according to claim 1 , comprising the following steps:
i) mixing the compound of formula (I) in a part of the solvent to yield a solution A,
ii) mixing the viscosity-enhancing agent in the remaining part of the solvent to yield a solution B, and
iii) mixing solutions A and B to yield the pharmaceutical composition.
22. A method for treating papillomavirus infection comprising the administration to a person in need thereof of an effective amount of a pharmaceutical composition according to claim 1 .
23. The method according to claim 22 , wherein the papillomavirus infection is an HPV6 or HPV11 infection.
24. A method for treating lesions or diseases associated with papillomavirus infections comprising administration to a person in need thereof of an effective amount of a pharmaceutical composition according to claim 1 .
25. The method according to claim 24 , wherein the lesions or diseases associated with papillomavirus infections are selected from anogenital warts, laryngeal, conjunctival or oral papillomas, recurrent respiratory papillomatosis, low-grade and high-grade intraepithelial neoplasia, bowenoid papulosis, common, plantar, myrmecia, superficial or flat warts, epidermodysplasia verruciformis, and carcinomas.
26. The method according to claim 24 , wherein the lesions or diseases associated with papillomavirus infections are selected from condyloma acuminata and condyloma lata.